15862-36-9

Usage

Uses

2,3-Dibromo-5-nitropyridine

InChI:InChI=1/C5H2Br2N2O2/c6-4-1-3(9(10)11)2-8-5(4)7/h1-2H

Upstream product

• 15862-33-6 3-bromo-2-hydroxy-5-nitropyridine 
• 5418-51-9 5-nitro-2-hydroxypyridine 

Downstream Products

• 74919-31-6 3-bromo-2-ethoxy-5-nitropyridine 
• 186593-43-1 5-amino-3-bromo-2-methylpyridine 
• 186593-42-0 3-bromo-2-methyl-5-nitropyridine 
• 1119090-69-5 ethyl 2-(6-(3-methoxyphenyl)-5-phenylpyridin-3-ylamino)-5-methylbenzoate 
• 1119085-69-6 2-(6-(3-methoxyphenyl)-5-phenylpyridin-3-ylamino)-5-methylbenzoic acid 
• 1119088-65-1 6-(3-methoxyphenyl)-5-phenylpyridin-3-amine 
• 1119088-71-9 2-(3-methoxyphenyl)-5-nitro-3-phenylpyridine 
• 1119088-68-4 3-bromo-2-(3-methoxyphenyl)-5-nitropyridine 

Relevant academic research and scientific papers

Compounds for inflammation and immune-related uses

The invention relates to certain compounds or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

IMIDAZOLE BIARYL COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

The present disclosure is directed to compounds of formula (Ie) and pharmaceutically acceptable salts thereof, wherein A, B, R1, R2, m, n, X1, X2, X3 and X4 are as defined herein, which are active as inhibitors of S-Nitrosoglutathione reductase (GSNOR). These compounds prevent, inhibit, or suppress the action of GSNOR and are therefore useful in the treatment of GSNOR mediated diseases, disorders, syndromes or conditions such as, e.g., pulmonary hypertension, acute respiratory distress syndrome (ARDS), asthma, bronchospasm, cough, pneumonia, pulmonary fibrosis, interstitial lung diseases, cystic fibrosis and chronic obstructive pulmonary disease (COPD).

AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS

New azabiphenylaminobenzoic acid derivatives having the chemcial structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the dehydroorotate dihydrogenase (DHODH)

The Synthesis of the High-Potency Sweetener, NC-00637. Part 2: Preparation of the Pyridine Moiety

The pyridine moiety within the high-potency sweetener, NC-00637 (1), 5-amino-2-cyanopyridine (4), was prepared from 2-hydroxy-5-nitropyridine (10). The sequence involved the conversion of the hydroxy group to bromide followed by substitution with cyanide to give 2-cyano-5-nitropyridine (8). Reduction of the nitro group proved to be troublesome when catalytic hydrogenation was used. Iron with an acid gave a reproducible reaction that could be used at scale.